Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Infections

Rare Diseases

Lymphoma

Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Burkitt Lymphoma

Leukemia, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Leukemia, Lymphoid

Hematologic Diseases

Chronic Disease

Disease Attributes

Lymphosarcoma

Chronic Lymphocytic Leukemia

Chronic Graft Versus Host Disease

B-cell Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Anti-Infective Agents

Antirheumatic Agents

Antiemetics

Gastrointestinal Agents

Dermatologic Agents

Reproductive Control Agents

Micronutrients

Hematinics

Vitamins

Etoposide

Hydrocortisone

Hydrocortisone 17-butyrate 21-propionate

Hydrocortisone acetate

Hydrocortisone hemisuccinate

Cytarabine

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Dexamethasone

Methotrexate

Prednisone

Rituximab

Vincristine

Ifosfamide

Dexamethasone acetate

Etoposide phosphate

Vindesine

Isophosphamide mustard

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antineoplastic Agents, Immunological

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antimetabolites

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antiviral Agents

Tubulin Modulators

Antimitotic Agents

Folinic Acid

Folate

Vitamin B9

Pts with biological age up to 55 y with advanced stage will receive 6 cycles of intensive treatment: blocks (A1-B1-C1-A2-B2-C2). If after A1 and B1 cycles CR is observed, the rest of the cycles will be administered with reduced doses.

In pts with biological age \>55 y with advanced stage block will receive A and B with attenuated doses (A1\*-B1\*-A2\*-B2\*-A3\*-B3\*).

Pts with biological age up to 55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 blocks. If CR is not reached, patients will complete the 6 treatment cycles.

Pts with a biological age \>55 y with localized stage (non-bulky I or II) with CR after 2 cycles will finish treatment after 4 attenuated blocks (A1\*-B1\*-A2\*-B2\*). If CR is not reached, patients will complete the 6 cycles of treatment.

Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.

Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*

Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.

Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).

Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*.

Iphosphamid

Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*

Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.

Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*

Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*

Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*

Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2

Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2

Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*

Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2

Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.

Carmen López-Carrero

Olga García Calduch

JOSEP MARIA RIBERA SANTASUSANA

JUAN MANUEL SANCHO CIA

Rodrigo Martino

Irene García Cadenas

Eva Gimeno

Pere Barba

Pau Abrisqueta

Santiago Mercadal

Clara Maluquer

Cristina Barrenetxea

Juan Miguel Bergua

Josefina Serrano

Izaskun Ceberio

Nerea Caminos

Maialen Sirvent

Maria Teresa Artola

Carlos Rodríguez

Antoni Garcia Guiñon

Buenaventura Buendía

Ana Jiménez

Mariana Bastos

Daniel García Belmonte

Laura Llorente

PIlar Herrera

Pilar Herrera

Reyes Arranz

Maria Paz Queipo de Llano

Teresa Bernal

Antònia Cladera

Jesús María Hernández-Rivas

Jesús Maria Hernández-Rivas

Maria José Penalva

Natalia Alonso

Marta Cervera

Ana Vicent

Ferran Vall-Llovera

Ana Sebrango

Maria José Terol

Pau Montesinos

Maria Paz Martínez Badas

JOSEP MARIA RIBERA SANTASUSANA, M.D.; Ph.D.

JUAN MANUEL SANCHO CIA, M.D.; Ph.D.

Rituximab combined with a specific intensive chemotherapy is considered the standard treatment for newly diagnosed patients with mature B leukemia/lymphoma. However, the toxicity of this therapy is high. The purpose of this trial is to reduce the dose intensity of the chemotherapy blocks once the patient has achieved complete response. With this approach the investigators expect to maintain the efficacy and to reduce the toxicity of the chemotherapy, specially the rate of deaths in complete response.

Patients younger than 55 years in complete response after two blocks of rituximab and specific intensive chemotherapy will receive four additional blocks of rituximab and attenuated chemotherapy (reduction by 33% of the dose of cyclophosphamide, methotrexate and cytarabine) followed by additional rituximab doses as consolidation. Patients older than 55 years will receive the six blocks with attenuated chemotherapy.

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Defined as the time from diagnosis to death by any cause or last follow-up.

Defined as the time from diagnosis to progression disease, relapse or death by any cause or last follow-up.

Number of patients experiencing different toxicities during the treatment period, classified according to severity and graded according to NCTCAE V4.0

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

PETHEMA Foundation

Spots Global Cancer Trial Database for iphosphamid

Every month we try and update this database with for iphosphamid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for iphosphamid

Every month we try and update this database with for iphosphamid cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for iphosphamid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.